TrialNature communications2024

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial.

Yu-Chun Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.